490 related articles for article (PubMed ID: 23880230)
1. Advanced Parkinson's disease: clinical characteristics and treatment. Part II.
Kulisevsky J; Luquin MR; Arbelo JM; Burguera JA; Carrillo F; Castro A; Chacón J; García-Ruiz PJ; Lezcano E; Mir P; Martinez-Castrillo JC; Martínez-Torres I; Puente V; Sesar A; Valldeoriola-Serra F; Yañez R
Neurologia; 2013; 28(9):558-83. PubMed ID: 23880230
[TBL] [Abstract][Full Text] [Related]
2. [Treatment possibilities in advanced Parkinson's disease].
Takáts A; Nagy H; Radics P; Tóth A; Tamás G
Ideggyogy Sz; 2013 Nov; 66(11-12):365-71. PubMed ID: 24555235
[TBL] [Abstract][Full Text] [Related]
3. Use of advanced therapies for Parkinson's disease in Norway.
Ezat B; Pihlstrøm L; Aasly J; Tysnes OB; Egge A; Dietrichs E
Tidsskr Nor Laegeforen; 2017 May; 137(9):619-623. PubMed ID: 28468476
[TBL] [Abstract][Full Text] [Related]
4. Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus.
De Gaspari D; Siri C; Landi A; Cilia R; Bonetti A; Natuzzi F; Morgante L; Mariani CB; Sganzerla E; Pezzoli G; Antonini A
J Neurol Neurosurg Psychiatry; 2006 Apr; 77(4):450-3. PubMed ID: 16543520
[TBL] [Abstract][Full Text] [Related]
5. When the going gets tough: how to select patients with Parkinson's disease for advanced therapies.
Worth PF
Pract Neurol; 2013 Jun; 13(3):140-52. PubMed ID: 23487815
[TBL] [Abstract][Full Text] [Related]
6. The Choice Between Advanced Therapies for Parkinson's Disease Patients: Why, What, and When?
Dijk JM; Espay AJ; Katzenschlager R; de Bie RMA
J Parkinsons Dis; 2020; 10(s1):S65-S73. PubMed ID: 32651333
[TBL] [Abstract][Full Text] [Related]
7. [Candidate patient for treatment with continuous apomorphine infusion].
Martí MJ; Kulisevsky J
Rev Neurol; 2012; 55 Suppl 1():S15-9. PubMed ID: 23169228
[TBL] [Abstract][Full Text] [Related]
8. Motor features and response to oral levodopa in patients with Parkinson's disease under continuous dopaminergic infusion or deep brain stimulation.
Elia AE; Dollenz C; Soliveri P; Albanese A
Eur J Neurol; 2012 Jan; 19(1):76-83. PubMed ID: 21645174
[TBL] [Abstract][Full Text] [Related]
9. [Advanced Parkinson's disease: clinical characteristics and treatment (part 1)].
Kulisevsky J; Luquin MR; Arbelo JM; Burguera JA; Carrillo F; Castro A; Chacón J; García-Ruiz PJ; Lezcano E; Mir P; Martinez-Castrillo JC; Martínez-Torres I; Puente V; Sesar A; Valldeoriola-Serra F; Yañez R
Neurologia; 2013 Oct; 28(8):503-21. PubMed ID: 23856182
[TBL] [Abstract][Full Text] [Related]
10. The role of subcutaneous infusion of apomorphine in Parkinson's disease.
Wenzel K; Homann CN; Fabbrini G; Colosimo C
Expert Rev Neurother; 2014 Jul; 14(7):833-43. PubMed ID: 24917215
[TBL] [Abstract][Full Text] [Related]
11. [Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety].
Annic A; Devos D; Seguy D; Dujardin K; Destée A; Defebvre L
Rev Neurol (Paris); 2009; 165(8-9):718-27. PubMed ID: 19150100
[TBL] [Abstract][Full Text] [Related]
12. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
Chen JJ; Obering C
Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
[TBL] [Abstract][Full Text] [Related]
13. [Device-aided therapies in advanced Parkinson's disease].
Timofeeva AA
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(12):54-60. PubMed ID: 28139627
[TBL] [Abstract][Full Text] [Related]
14. [Application of levodopa/carbidopa intestinal gel in advanced Parkinson's disease].
Toth A; Nagy H; Wacha J; Bereczki D; Takáts A
Neuropsychopharmacol Hung; 2015 Dec; 17(4):191-6. PubMed ID: 26727723
[TBL] [Abstract][Full Text] [Related]
15. [Current treatment strategies for Parkinson's disease].
Südmeyer M; Wojtecki L; Schnitzler A
Fortschr Neurol Psychiatr; 2011 Dec; 79(12):733-43. PubMed ID: 22161168
[No Abstract] [Full Text] [Related]
16. Infusion treatments and deep brain stimulation in Parkinson's Disease: The role of nursing.
De Rosa A; Tessitore A; Bilo L; Peluso S; De Michele G
Geriatr Nurs; 2016; 37(6):434-439. PubMed ID: 27444659
[TBL] [Abstract][Full Text] [Related]
17. Drugs for Parkinson's disease.
Treat Guidel Med Lett; 2013 Nov; 11(135):101-6. PubMed ID: 24165688
[TBL] [Abstract][Full Text] [Related]
18. Comparison of apomorphine and levodopa infusions in four patients with Parkinson's disease with symptom fluctuations.
Nyholm D; Constantinescu R; Holmberg B; Dizdar N; Askmark H
Acta Neurol Scand; 2009 May; 119(5):345-8. PubMed ID: 18822087
[TBL] [Abstract][Full Text] [Related]
19. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
Deleu D; Hanssens Y; Northway MG
Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
[TBL] [Abstract][Full Text] [Related]
20. Apomorphine infusion in advanced Parkinson's patients with subthalamic stimulation contraindications.
Drapier S; Gillioz AS; Leray E; Péron J; Rouaud T; Marchand A; Vérin M
Parkinsonism Relat Disord; 2012 Jan; 18(1):40-4. PubMed ID: 21890396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
